Haggai Bar-Yoseph (H Bar-Yoseph)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 7

Top Topics

Microbial Community

Ulcerative Colitis

Antibiotic Resistance Genes

Top Venues

JPEN. Journal of parenteral and enteral nutrition

Alimentary pharmacology & therapeutics

International journal of colorectal disease

Digestive diseases and sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Haggai Bar-Yoseph, Avril Metcalfe-Roach, Mihai Cirstea, B Brett Finlay
Microbiome changes under enteral deprivation are dynamic and dependent on intestinal location. JPEN. Journal of parenteral and enteral nutrition 48 (4) (2024)
Haggai Bar-Yoseph, Avril Metcalfe-Roach, Mihai Cirstea, B Brett Finlay
Microbiome changes under enteral deprivation are dynamic and dependent on intestinal location. JPEN. Journal of parenteral and enteral nutrition (2024)
Netta Glaubach, Dana Ben Hur, Alexander Korytny, Yoni Isenberg, Yousef Laham, Ronit Almog, Irit Chermesh, Roni Weisshof, Haggai Bar-Yoseph
The Association Between Low Body-Mass Index and Serious Post-endoscopic Adverse Events. Digestive diseases and sciences (2023)
Anton Bermont, Efrat Broide, Shay Matalon, Vered Richter, Tsilia Lazarovitch, Haggai Bar-Yoseph, Haim Shirin
New-Onset of Crohn's Disease Is Associated with Antistreptolysin O Positive Titers. Clinical and experimental gastroenterology 13 (2020)
Haggai Bar-Yoseph, Haneen Daoud, Dana Ben Hur, Yehuda Chowers, Matti Waterman
Does early corticosteroid therapy affect prognosis in IBD patients hospitalized with Clostridioides difficile infection? International journal of colorectal disease 35 (3) (2020)
Haggai Bar-Yoseph, Y Chowers
Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained? Alimentary pharmacology & therapeutics 45 (11) (2017)
Haggai Bar-Yoseph, N Levhar, L Selinger, U Manor, M Yavzori, O Picard, E Fudim, Uri Kopylov, R Eliakim, S Ben-Horin, Y Chowers, Bella Ungar
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Alimentary pharmacology & therapeutics 47 (2) (2017)